In this article
🧪 Load this blend into the DIY blend calculator →
What it is
CagriSema is a set pairing of two research compounds that is still under formal study. It combines Cagrilintide, a long-acting amylin analog (a lab-made copy of a natural body-signal molecule called amylin, built to stay active longer), with Semaglutide, a GLP-1 receptor agonist (a compound that activates a specific docking protein in the body called the GLP-1 receptor). This is a named pharmaceutical combination under active research, not a casual community-mixed blend.
Why these are combined
Amylin and GLP-1 work on separate appetite-control pathways. Think of them like two different light switches that both dim the same room, but each switch is on a different wall. Using both together is studied to see if their effects add up.
Results from research trials have shown a larger body-weight change for the combination than for either compound used on its own.
Key point: Combining Cagrilintide and Semaglutide targets two separate appetite-control pathways. Research trials have shown a larger body-weight change with the combination than with either compound alone.
The components
- Cagrilintide, a long-acting amylin analog, studied for its effect on appetite signaling.
- Semaglutide, a GLP-1 receptor agonist, studied for its effect on appetite and metabolic markers.
Reconstitution and blending
These research compounds come as a dry powder. At the bench, the powder is reconstituted (dissolved into a liquid solution) using bacteriostatic water. Bacteriostatic water is a specially purified water with a small preservative added to slow bacterial growth in the vial. The two compounds are studied together as a single, fixed formulation.
Our reconstitution and DIY blend calculators handle the per-cartridge volumes and beyond-use timing once you have decided what shares a cartridge.
Status in sport
GLP-1 and amylin agonists are not currently on the WADA Prohibited List. WADA (the World Anti-Doping Agency) maintains a list of substances that are banned in competitive sport.
As of the 2026 cycle, GLP-1 compounds appear on the WADA Monitoring Program. That means they are being tracked and watched, but are not yet banned. This status can change in future list cycles.
Related reading
- Cagrilintide
- Semaglutide
- Full peptide reference library and stacking guide
- Reconstitution and blend calculators
Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.
Frequently asked questions
What is CagriSema and how do its two components differ mechanistically?
CagriSema pairs Cagrilintide, a long-acting amylin analog, with Semaglutide, a GLP-1 receptor agonist. Each acts on a distinct appetite-signaling pathway; the fixed combination is studied to evaluate whether the two mechanisms produce additive effects.
Why do researchers study Cagrilintide and Semaglutide together rather than separately?
Amylin and GLP-1 pathways operate independently. Research trials have shown greater body-weight change with the combination than with either compound studied alone, suggesting the two pathways may complement each other.
Is CagriSema or its components banned under WADA rules for 2026?
GLP-1 compounds appear on the 2026 WADA Monitoring Program , tracked but not currently prohibited. Amylin agonists are not on the Prohibited List. WADA classification can change in future annual cycles.
What the research community gets wrong about CagriSema
- It is two peptides, not one. CagriSema pairs Cagrilintide and Semaglutide. At the bench you are handling two separate research compounds, so label and track each one instead of treating the vial as a single ingredient.
- It is a fixed, studied formulation, not a blend you invent. The pairing and its ratio come from published research, not from guesswork. Treat it as a set recipe rather than something to change on a whim.
- The two compounds are not interchangeable. Cagrilintide (an amylin analog) and Semaglutide (a GLP-1 receptor agonist) are different molecules with different sizes. Do not assume they dissolve, look, or store the same way.
- Trial weight-change results describe the study material, not your vial. Reports of larger body-weight change come from clinical studies of the compounds. They say nothing about any solution you reconstitute at a bench, and this page is research reference only.
- A reconstituted vial does not stay good forever. Peptides in solution can break down over time, and rough handling (shaking hard enough to foam) can damage them. Note your reconstitution date and store the vial the way your protocol calls for.
From our bench: If you have reconstituted a CagriSema research vial, tell us what you actually saw. How long did the powder take to fully dissolve in bacteriostatic water, was the final solution clear or cloudy, and did any particles or haze show up after it sat in the fridge? Share your own logged observations (not numbers copied from a label) so other researchers can compare notes.
Sources
- Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
- Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
- Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med, 2025. PMID 40544433
- PubChem Compound Summary: Cagrilintide (CID 171397054)
- PubChem Compound Summary: Semaglutide (CID 56843331)
✔ Reviewed by Bryan Le, PharmD, RPh
Bryan is a licensed pharmacist (Doctor of Pharmacy, Registered Pharmacist). Reconstituting lyophilized preparations is core pharmacy practice, so he reviews The Lab’s content for technical accuracy and to keep it within a research-and-education scope, with no medical or dosing advice. View profile on LinkedIn.
